# Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.

> **NCT06208137** · NA · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 456 (estimated)

## Conditions studied

- Transplant-Related Disorder

## Interventions

- **BEHAVIORAL:** Health monitoring and regular return follow-up reminders

## Key facts

- **NCT ID:** NCT06208137
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2027-10-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 456 (ESTIMATED)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06208137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06208137, "Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06208137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*